Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory follicular lymphoma
2020-005239-53Phase 3Active
- Sponsor
- Roche
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mosunetuzumab, lenalidomide and rituximab in follicular lymphoma (FL) (3 arms), sponsored by Roche. Primary endpoint: Progression-free survival by independent review committee. Started Sep 2021; status: active.
02
Drugs
mosunetuzumablenalidomiderituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2020-005239-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005239-53.